AstraZeneca Financial Statements
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AstraZeneca revenue and earnings
In fiscal 2025, AstraZeneca generated $58.74 billion in revenue, up 8.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $10.22 billion (+45.3% year over year), for a net margin of 17.4% versus a median of 12.0% in the prior 5 years. Gross margin was 81.9% (up from 81.1%) and operating margin 23.4%.
Diluted earnings per share came in at $6.54, up from $4.50. Over the last 5 fiscal years, AZN's revenue has grown at a 17.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
AstraZeneca income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.74B | 54.07B | 45.81B | 44.35B | 37.42B | 26.62B | 24.38B | 22.09B | 22.46B | 23.00B |
| Revenue growth (YoY) | +8.63% | +18.03% | +3.29% | +18.53% | +40.58% | +9.16% | +10.38% | -1.67% | -2.33% | -6.90% |
| Cost of Revenue | 10.63B | 10.21B | 8.27B | 12.39B | 12.44B | 5.30B | 4.92B | 4.94B | 4.32B | 4.13B |
| Gross Profit | 48.11B | 43.87B | 37.54B | 31.96B | 24.98B | 21.32B | 19.46B | 17.15B | 18.15B | 18.88B |
| Operating Expenses | 34.36B | 33.86B | 29.35B | 28.20B | 23.92B | 16.16B | 16.54B | 13.77B | 14.47B | 13.97B |
| Research & Development | 14.23B | 13.58B | 10.94B | 9.76B | 9.74B | 5.99B | 6.06B | 5.93B | 5.76B | 5.89B |
| Selling, General & Admin | 19.93B | 19.98B | 19.22B | 18.42B | 15.23B | 11.29B | 11.68B | 10.03B | 10.23B | 9.41B |
| Operating Income | 13.74B | 10.00B | 8.19B | 3.76B | 1.06B | 5.16B | 2.92B | 3.39B | 3.68B | 4.90B |
| Interest Expense | 1.69B | 1.74B | 1.63B | 1.35B | 1.30B | 1.31B | 1.43B | 1.42B | 1.51B | 1.38B |
| Pretax Income | 12.40B | 8.69B | 6.90B | 2.50B | -265.00M | 3.92B | 1.55B | 1.99B | 2.23B | 3.55B |
| Income Tax | 2.17B | 1.65B | 938.00M | -792.00M | -380.00M | 772.00M | 321.00M | -57.00M | -641.00M | 146.00M |
| Net Income | 10.22B | 7.04B | 5.96B | 3.29B | 112.00M | 3.20B | 1.33B | 2.15B | 3.00B | 3.50B |
| Net Income growth (YoY) | +45.34% | +18.14% | +81.11% | +2835.71% | -96.50% | +139.40% | -38.05% | -28.19% | -14.23% | +23.86% |
| EPS (Basic) | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 |
| EPS (Diluted) | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.76 |
| Shares Outstanding (Basic) | 1.55B | 1.55B | 1.55B | 1.55B | 1.42B | 1.31B | 1.30B | 1.27B | 1.27B | 1.26B |
| Shares Outstanding (Diluted) | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B |
| Gross Margin | 81.90% | 81.12% | 81.95% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% |
| Operating Margin | 23.40% | 18.50% | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% |
| Net Margin | 17.41% | 13.01% | 13.00% | 7.41% | 30.00% | 12.01% | 5.47% | 9.76% | 13.36% | 15.21% |
This table shows 10 annual periods of AstraZeneca's income statement, from FY 2025 back to FY 2016, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AZN's reporting calendar. What is a income statement?